Search

Objective To explore the role of CD200 in Ewing's sarcoma and its possible pathological mechanisms, and to search for potential drugs that can improve the survival prognosis of Ewing's sarcoma patients. Methods The RNA seq and clinical data of Ewing's sarcoma patients were obtained from the International Cancer Genome Consortium database. The survival analysis was used to explore the impact of CD200 on the survival prognosis of Ewing's sarcoma patients. The gene set enrichment analysis (GSEA) and Lincx analysis were carried out to find the molecular mechanism of CD200 promoting the malignant process of Ewing's sarcoma and the anti-Ewing's sarcoma drugs that may target CD200. The expression level of CD200 was verified by RT qPCR. Results CD200 was significantly overexpressed in Ewing's sarcoma cells (P

BackgroundIt is still controversial whether or not serum uric acid, a key risk for coronary heart disease, is significantly associated with prognosis of acute myocardial infarction (AMI) . And there are rare large-scale and multicenter studies on serum uric acid and long prognosis of AMI in China.ObjectiveTo investigate the relationship between serum uric acid and long-term prognosis in AMI patients.MethodsOne thousand and ninety-eight AMI patients from 9 hospitals (Chengdu First People's Hospital, Chengdu Second People's Hospital, the Third People's Hospital of Chengdu, the First Affiliated Hospital of Chengdu Medical College, Dujiangyan Medical Center, Pidu District People's Hospital, Chengdu, Shuangliu District First People's Hospital, Jintang First People's Hospital, the People's Hospital of Pengzhou) in Chengdu during September 2016 to July 2019 were consecutively reSScruited. Baseline data were collected via the electronic medical record system of each hospital by trained professionals, including: (1) demographic data: age, gender, prevalence of smoking; (2) clinical complications and related information: hypertension, diabetes, blood pressure, heart rate, Killip class, AMI type (NSTEMI or STEMI) , prevalence of percutaneous coronary intervention (PCI) ; (3) laboratory parameters: serum SScreatinine (Scr) , uric acid (UA) , triglyceride (TG) , total cholesterol (TC) , low-density lipoprotein cholesterol (LDL-C) , high-density lipoprotein cholesterol (HDL-C) , estimated glomerular filtration rate (eGFR) ; (4) post-discharge medication: aspirin, clopidogrel/tigrelol, statins, Beta-blockers, ACEI/ARB, diuretics. Baseline data were compared between patients with and without major adverse cardiovascular and cerebrovascular events (MACCE) during post-discharge follow-up. Then, prognosis was compared aSScross UA tertile subgroups〔A: UA

Objective To explore the prognostic factors that affect patients with advanced esophageal cancer treated with Traditional Chinese medicine (TCM). Methods A total of 72 patients with stage IV esophageal cancer were selected for analysis, and the advantaged and disadvantaged groups of TCM treatment were defined according to survival time. The log-rank method was used for the univariate analysis, the rank-sum test was used for the correlation between the syndrome type and the prognostic grouping, and the Cox proportional risk model was used for multiple factors. Results The median survival of the 72 patients with esophageal cancer was 17.9 months. The univariate analysis of the result showed that the presence of organ metastasis, the presence of lung metastasis, and the post-treatment symptom self-assessment and length of herbal medication were related to the prognosis of advanced esophageal cancer treated with TCM. The rank-sum test between the TCM syndrome elements, and survival prognosis grouping showed that the syndrome element of Qi stagnation may also affect prognosis. The result of the multi-factorial analysis showed that the factor of the duration of the TCM administration was an independent factor that affects the prognosis of advanced esophageal cancer treated with TCM. Conclusion The duration of TCM treatment affected the prognosis of patients with advanced esophageal cancer. [ABSTRACT FROM AUTHOR]

Objective To investigate the differences between clinicopathological features and prognosis of alpha-fetoprotein (AFP) negative (AFP < 20 ng/ml) and positive (AFP ⩾ 20 ng/ml) hepatocellular carcinoma (HGC) patients. Methods clinicopathological data of 142 AFP-negative and 109 AFP-positive HCG patients who underwent R0 radical hepatectomy in the Cancer Hospital of Chinese Academy of Medical Sciences between January 2006 and December 2011 were retrospectively reviewed and analyzed in this study. Results Compared with the AFP-negative patients, a higher female to male sex ratio, the later Barcelona Clinic Liver Cancer (BCLC) stage, more liver capsule invasion and poorer Edmondson-Steiner grade were in the AFP-positive cases (P<0.05 for all). Furthermore, the 1-, 3-, and 5-year overall survival rates were 94.4%, 82.4% and 61.0% in the AFP-negative group and 87.2%, 61.1% and 40.2%, respectively, in the AFP-positive group (P<0.001). The multivariate analysis with Cox's proportional hazards model showed that AFP status, tumor size and Edmondson-Steiner grade are independent risk factors for survival of all the patients (P<0.05) , and large tumor and Edmondson-Steiner grades III/IV are independent risk factors for worse survival in AFP-negative patients (P<0.05). However, large tumor diameter was proved to be an independent risk factor leading to poor prognosis of AFP-positive cases (P<0.05). Conclusion High levels of AFP indicate that the tumors are more malignant and with unfavorable prognosis. [ABSTRACT FROM AUTHOR]